Bionova Scientific initiates expansion project to quadruple GMP biologics manufacturing capacity

Following Bionova Scientific’s recent integration into the Asahi Kasei Group, project is the first phase of a wider strategic initiative to expand capacity and enhance end-to-end biologics development and manufacturing services.

Fremont, CA   February 1, 2023 – Bionova Scientific, an Asahi Kasei Group company and full-service biologics CDMO, announced that it has commenced commissioning of a third facility in Fremont, California, which will enable the company to significantly scale-up its manufacturing capacity and service capabilities. The expansion also marks the start of a long-term strategic initiative by the company – supported by the Asahi Kasei Group – to broaden its services portfolio to cover an even wider range of technical capabilities and therapeutic modalities, in response to diversifying customer requests.

Bionova Scientific currently operates two facilities in Fremont: a headquarters and state-of-the-art development and GMP manufacturing facility on West Warren Avenue, and a nearby dedicated warehouse and storage facility on Fremont Boulevard. The new facility, located on Laurelview Court, will act as a replacement headquarters and development center, housing Bionova Scientific’s administrative functions and biologics development teams that are currently located in the West Warren facility. In turn, the West Warren facility will become devoted to manufacturing operations, using advanced single-use equipment systems. The administrative offices and the labs for cell line development, process development and analytical services are expected to be moved to the Laurelview facility in mid-2023, making room for Bionova Scientific to quadruple its current biologics GMP manufacturing capacity in the West Warren facility shortly thereafter.

Bionova Headquarters - Fremont , CA

Bionova’s new Laurelview Court facility.

Darren Head, CEO of Bionova Scientific, commented, “We are very excited to begin our strategic expansion with this new facility. Bionova was founded on the core belief that our success will only come from providing science-first, client-focused services. Adding the Laurelview development facility gives all our technical teams the opportunity to grow and deepen their expertise so we can continue to provide that science-first focus our clients have come to expect and depend upon. Our cell line development, process development and analytical services teams will each have more capacity and resources for development projects. Increasing our GMP manufacturing footprint in the West Warren facility will let us offer our clinical and commercial clients more manufacturing slots to meet their timelines.”

About Bionova Scientific
Founded in 2014 and acquired by the Asahi Kasei Group in 2022, Bionova offers world-class biologics CDMO services built on a foundation of strong process development and analytical science with a staff that brings decades of experience in late stage and commercial launch projects. With its high quality, customized biomanufacturing services, cutting-edge process development expertise and data-driven risk minimization strategies, the company is renowned for helping client projects move quickly from concept to robust GMP production. Bionova Scientific’s operations are optimized for multi-product manufacturing of monoclonal antibodies and other recombinant proteins. For more information, visit bionovascientific.com

About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 46,000 employees around the world, the company contributes to a sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit asahi-kasei.com and ak-bio.com.

Please submit any questions regarding this news item using the form below…